← Back to Pipeline Dashboard Open Source Medicine Foundation

PCV20

Phase 3 Clinical Trial

Developer: Vaxcyte, Inc.  |  Target Disease: Pneumococcal disease

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View Pneumococcal disease Vaccine Guide →
Development Phase Phase 3 Clinical Trial Primary Status
Platform Technology Biological (unspecified platform) Biologic Architecture
Target Indication Pneumococcal disease Pathogen / Antigen
Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Not Filed / Pre-submission
EMA (Europe) Not Filed / Pre-submission
Health Canada Not Filed / Pre-submission
TGA (Australia) Not Filed / Pre-submission

Scientific Profile & Documentation

Platform Architecture
Biological (unspecified platform)
Lead Developer
Vaxcyte, Inc.
Next Expected Milestone
Primary completion (most advanced trial): 2027-01 (registry estimate)
Analyst & Development Notes
Auto-grouped from 3 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation
ClinicalTrials.gov NCT07284654 →
Additional Sources & Literature

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT07284654 Phase 3 Clinical Trial

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Status: Active / Ongoing • Expected Readout: 2027-01
NCT07365826 Phase 3 Clinical Trial

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 5

Status: Active / Ongoing • Expected Readout: 2027-03
NCT07425392 Phase 3 Clinical Trial

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

Status: Active / Ongoing • Expected Readout: 2027-03

Milestone Overview

  • Stage Verification
    Phase 3 Clinical Trial confirmed as of 2026-07-10.
  • Target Milestone
    Primary completion (most advanced trial): 2027-01 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.